Key Stats for UnitedHealth Stock
- Current Price: $392.95
- Target Price (Mid): ~$720
- Street Target: ~$475
- Potential Total Return: ~84%
- Annualized IRR: ~15% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
UnitedHealth Group (UNH) did the hard part in July. On the 16th, it reported adjusted earnings of $6.38 per share, roughly 30% ahead of the $4.92 the Street modeled, and raised full-year guidance. Shares spiked toward a 52-week high on the print. Then they spent six weeks handing all of it back, closing at $392.95 on August 28 and erasing the entire post-earnings gain.
On August 26, Erste Group reportedly cut UNH to Hold from Buy. Days later, Bernstein’s Lance Wilkes kept his Buy and, per syndicated coverage, raised his target after a Centers for Medicare & Medicaid Services rate notice for 2027. A blowout quarter the market refused to pay up for, and two respected desks landing on opposite conclusions within days.
The Beat Was Real. The Fade Says the Market Wants Proof
Revenue landed at $112.03 billion, operating earnings of $8 billion grew 55% year over year, and the medical care ratio, the share of premium spent on member care, improved to 86.7% from 89.4% a year earlier, though $860 million of favorable prior-period development flattered that figure. Management raised adjusted EPS guidance to $19.50 to $20 and doubled the planned buyback to at least $5 billion for 2026, up from $2.5 billion.
The engine was Medicare Advantage. The drag was commercial, where cost trends ran modestly above 11%, and management pushed full margin recovery past 2027, later than it guided months ago. Commercial Group CEO Dan Kueter tied the pressure to an arbitration process under the No Surprises Act that he said select providers are exploiting, with roughly 60% of disputes brought by just five entities and arbiter payouts running 11 to 30 times Medicare rates. Management frames the commercial shortfall as delayed timing rather than lost margin, but the recovery clock keeps moving right. The market looked at an early Medicare turnaround sitting next to a late commercial repair and decided the July pop got ahead of itself.
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
Management Is Betting the Algorithm Still Holds
What the fade misses is how firmly management recommitted to its long-term growth target under direct questioning. Pressed by analysts on whether the outperformance was a one-off, Chairman and CEO Stephen Hemsley refused to walk back the company’s 13% to 16% earnings growth algorithm: “I don’t ever believe, I ever didn’t believe in the 13% to 16% long-term growth rate.” He argued the technology and productivity gains behind it are larger now than in the past, not smaller.
A step down to Hold reflects the round trip itself: the easy re-rating is done and the commercial clock just got longer. The reiterated Buy reflects the opposite read, that the 2027 Medicare rate backdrop is strengthening into next year. Worth noting how modest even the bull case is here: the $475 Street mean target sits only about 21% above the current $392.95, hardly euphoric for a stock the market once paid a steep premium to own. Both sides are weighting the same two-speed recovery differently.
UNH trades near 18 times next-twelve-month earnings, against a trailing P/E near 25 times, well below the premium multiple the market gave it for a decade. A 2.3% dividend yield and the doubled buyback pay to wait. The bear case is not that the multiple is rich; it is that the earnings base under it still has a leaking commercial segment.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $392.95
- Target Price (Mid): ~$720
- Potential Total Return: ~84%
- Annualized IRR: ~15% / year
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free!) >>>
TIKR’s mid-case values UNH at around $720, implying roughly 84% total return over about 4.3 years, or about 15% per year. The assumptions are modest rather than heroic. Revenue growth is modeled near 6% annually, carried by continued Medicare Advantage repricing and Optum’s re-centered value-based care model. The margin driver is net income margin recovering to around 5%, still below the 6%-plus UNH earned before the 2024 to 2025 cost cycle. The primary risk is the one Kueter described: if the commercial trend stays above 11% and the arbitration dynamic he flagged is not reformed, the margin rebuild slips again, and the earnings base erodes.
The upside is that Medicare keeps beating its own planning assumptions while commercial finally turns, and the stock re-rates on both earnings growth and a recovering multiple. The downside is that commercial repair keeps sliding past 2027 while regulatory pressure caps Medicare, leaving the stock stuck near its current range.
Conclusion
The next hard checkpoint is the third-quarter report, expected around late October, and the first line to read is the commercial cost trend. If it holds above 11% and management again extends the recovery timeline, Erste’s caution looks right and the stock stays range-bound. If commercial trend even flattens while Medicare keeps running below its planning assumptions, Bernstein’s read wins and the round trip becomes a base.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UnitedHealth on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
